Benitec Biopharma Inc BNTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $8.46
- Day Range
- $8.06–8.47
- 52-Week Range
- $8.06–16.76
- Bid/Ask
- $8.08 / $8.13
- Shares Outstanding
- 34.88M
- Market Cap
- $282.90M
- Volume/Avg
- 158,557 / 159,379
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.benitec.com
Valuation
|
Metric
|
BNTC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BNTC
Financial Strength
|
Metric
|
BNTC
|
|---|---|
Quick Ratio | 33.68 |
Current Ratio | 34.00 |
Interest Coverage | — |
Quick Ratio
BNTC
Profitability
|
Metric
|
BNTC
|
|---|---|
Return on Assets (Normalized) | −12.66% |
Return on Equity (Normalized) | −12.95% |
Return on Invested Capital (Normalized) | −16.63% |
Return on Assets
BNTC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<gZ?$r | LOCK|&t&t | $127B | |||
| Moderna Inc
MRNA
| LOCK|<SH@#<! | LOCK|$X | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LBg!?B | LOCK|>MZzb | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>bt&<Q< | LOCK|Z^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k%@%DG | LOCK|!Hk | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^%YxN$f | LOCK|cbcR? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!T#?D#rv | LOCK|>@cNN | $27B | |||
| Incyte Corp
INCY
| LOCK|Q^!PWz | LOCK|B^S | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|C!TRTQg | LOCK|MY | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|PJR&ft | LOCK|@# | $14B |
United States